<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03163511</url>
  </required_header>
  <id_info>
    <org_study_id>VC02-101</org_study_id>
    <nct_id>NCT03163511</nct_id>
  </id_info>
  <brief_title>A Safety, Tolerability, and Efficacy Study of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness</brief_title>
  <official_title>An Open-Label, First-In-Human Study Evaluating the Safety, Tolerability, and Efficacy of VC-02™ Combination Product in Subjects With Type 1 Diabetes Mellitus and Hypoglycemia Unawareness</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViaCyte</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>California Institute for Regenerative Medicine (CIRM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ViaCyte</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to test if VC-02™ combination product can be implanted
      subcutaneously in subjects with Type 1 Diabetes and Hypoglycemia Unawareness and maintained
      safely for up to two years. It will also test if VC-02 is an effective treatment for these
      subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2017</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There are two Cohorts in this study design. Cohort 1 enrolls up to 15 subjects total. After Cohort 1 enrollment is completed, Cohort 2 enrollment then occurs with up to an additional 60 subjects.</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all adverse events reported for Cohort 1 subjects</measure>
    <time_frame>Thru the Month 4 Visit</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in C-peptide for Cohort 2 subjects</measure>
    <time_frame>Baseline to the Month 6 Visit</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">75</enrollment>
  <condition>Type 1 Diabetes Mellitus With Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC-02 Combination Product; Up to six (6) VC-02-20 implants and up to two (2) VC-02-300 implants</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>VC-02 Combination Product; Up to ten units implanted of which up to six (6) are VC-02-300 implants and the rest are VC-02-20 implants.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>VC-02 Combination Product</intervention_name>
    <description>PEC-01 cells loaded into a Delivery Device</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>PEC-Direct</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and non-pregnant women

          -  Diagnosis of T1DM for a minimum of five (5) years

          -  Hypoglycemia unawareness or significant glycemic lability

          -  Stable diabetic treatment

          -  Willingness to use a continuous glucose meter

          -  Acceptable candidate for implantation

        Exclusion Criteria:

          -  History of islet cell, kidney, and/or pancreas transplant.

          -  Six (6) or more severe, unexplained hypoglycemic events within six (6) months of
             enrollment

          -  Uncontrolled or untreated thyroid disease or adrenal insufficiency

          -  Diabetic complications such as severe kidney disease or renal dysfunction,
             proliferative retinopathy, diabetic foot ulcers, amputations attributable to diabetes,
             and/or severe peripheral neuropathy

          -  Non-compliance with current anti-diabetic regimen

          -  Detectable stimulated serum C-peptide during screening period assessment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>UCLA-UCI Alpha Stem Cell Clinic</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>949-824-3990</phone>
      <email>islet@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92121</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>844-317-7836</phone>
      <email>alphastemcellclinic@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>410-614-0905</phone>
      <email>apage20@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>612-626-4993</phone>
      <email>kreel001@umn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>614-688-6257</phone>
      <email>amber.anaya@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Alberta</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Study Coordinator</last_name>
      <phone>780-407-1501</phone>
      <email>parastoo@islet.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of British Columbia</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Enrolling by invitation</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 23, 2017</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

